Medifast, Inc.
NYSE:MEDPersonal Products & Services
-$0.01 today
- Market cap
- $136.43M
- Beta
- 0.66
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.82
Volume 0.09M
Average 0.21M
MED Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Medifast, Inc.NYSE: MED
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin narrows to -2.8%
Net margin was -2.8% in Q1 FY2026, down 2.1 pp from a year earlier. On a trailing-twelve-month basis it was -5.8%, down 4.5 pp year over year. Over 3 fiscal years it narrowed by 13.8 pp.
Context
- Net margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 1 analysts of -3.3% for the fiscal year ending Dec 2026, up from -4.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -2.8%+21.3 pp QoQ
- Last fiscal yearDec 2025
- -4.8%-5.2 pp YoY
- LTMMar 2026
- -5.8%-4.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -2.1 pp | -12.3 pp | -10.2 pp |
| 1 year | -5.2 pp | +1.6 pp | +6.8 pp |
| 3 years | -13.8 pp | — | — |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -4.8%
- Year-over-year change
- -5.2pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -4.8% | -5.2pp |
| FY2024 | 2024-12-31 | 0.3% | -8.9pp |
| FY2023 | 2023-12-31 | 9.3% | +0.3pp |
| FY2022 | 2022-12-31 | 9.0% | -1.8pp |
| FY2021 | 2021-12-31 | 10.7% | — |
Net Margin vs competitors
How MED compares with its peers on the latest reported figures
- MED's LTM Mar 2026 net margin of -5.8% is the 6th highest of the 10 companies compared; the peer median is -5.0%.
- Its year-over-year change of -4.5 pp is the 8th highest of 10, against a peer median of -0.7 pp.
- Over three fiscal years its change of -13.8 pp compares with a peer median of +2.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Dec 2025 | 5.6% | +1.0 pp | +1.6 pp | |
| LTM Jan 2026 | 3.9% | -4.1 pp | +8.3 pp | |
| LTM Feb 2026 | 1.6% | +3.7 pp | -11.6 pp | |
| LTM May 2026 | -1.3% | -2.2 pp | -4.6 pp | |
| LTM Mar 2026 | -5.0% | -0.7 pp | +23.6 pp | |
| LTM Mar 2026 | -5.8% | -4.5 pp | -13.8 pp | |
| FY2025 | -11.4% | -18.0 pp | -18.8 pp | |
| LTM Mar 2026 | -12.3% | +10.4 pp | +8.0 pp | |
| LTM Mar 2026 | -17.7% | +13.4 pp | +3.5 pp | |
AIIORobo.ai Inc. | FY2025 | -17614.9% | -16176.6 pp | — |
| Peer median (excluding MED) | -5.0% | -0.7 pp | +2.6 pp | |
Competitors are the stored peer set for MED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.53B | 1.6B | 1.07B | 602.46M | 385.79M |
| Cost of Revenue | 398.49M | 458.16M | 296.2M | 157.84M | 110.6M |
| Gross Profit | 1.13B | 1.14B | 775.85M | 444.62M | 275.19M |
| Gross Margin | 73.9% | 71.3% | 72.4% | 73.8% | 71.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Operating Expenses | 911.36M | 955.61M | 649.45M | 441.75M | 289.4M |
| Depreciation & Amortization | 6.81M | 10.98M | 13.11M | 12.71M | 10.5M |
| EBITDA | 222.94M | 195.74M | 141.9M | 16.49M | 4.86M |
| EBITDA Margin | 14.6% | 12.2% | 13.2% | 2.7% | 1.3% |
| Operating Income | 216.24M | 184.81M | 126.4M | 2.88M | (14.21M) |
| Operating Margin | 14.2% | 11.6% | 11.8% | 0.5% | -3.7% |
| Interest Income | 0 | 0 | 2.49M | 4.8M | 5.52M |
| Interest Expense | 231K | 701K | 0 | 0 | 0 |
| Other Income / Expenses | (112K) | (747K) | 2.4M | 909K | 8.57M |
| Income Before Tax | 216.13M | 184.06M | 128.8M | 3.79M | (5.64M) |
| Pre-Tax Margin | 14.2% | 11.5% | 12.0% | 0.6% | -1.5% |
| Income Tax Expense | 52.1M | 40.49M | 29.38M | 1.7M | 13.03M |
| Net Income | 164.03M | 143.57M | 99.42M | 2.09M | (18.67M) |
| Net Margin | 10.7% | 9.0% | 9.3% | 0.3% | -4.8% |
| EPS (Basic) | 14.01 | 12.82 | 9.10 | 0.19 | (1.70) |
| EPS (Diluted) | 13.89 | 12.73 | 9.10 | 0.19 | (1.70) |
| Weighted Avg Shares | 11.71M | 11.2M | 10.88M | 10.93M | 10.98M |
| Weighted Avg Shares (Diluted) | 11.81M | 11.28M | 10.92M | 10.96M | 10.98M |
Medifast, Inc.
NYSE:MED
Intrinsic Alpha fair value
Locked
Current Price
$12.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.